Retraction Watch has been a great resource for those of us who have been following research misconduct. They widely cover and conduct research on retractions, corrections, and other developments in this space. Unfortunately, there’s been plenty to write about even just within the stem cell and cell therapy arena, which is my primary interest. Think …
CRISPR gene editing has made rapid progress heading from bench to bedside. Perhaps the fastest has been its progress toward clinical use to combat sickle cell disease. We’ll start with a new paper on one major effort here. CRISPR gene editing. This process often involves cutting DNA, which then can be used as an opening to …
Weekly reads: CRISPR sickle cell, Parkinson’s, pig-human chimera concerns Read More »
Many avenues are being pursued to get stem cell therapy to the clinic for eye conditions. These different approaches employ a variety of stem cell types. In some cases, such as with iPS cells, the stem cells themselves are not transplanted. Instead, the iPS cells are used to make differentiated eye cells, such as RPE …
Weekly reads: stem cell therapy for eyes research, DMD, cheating death, cancer sensors Read More »
I’ve been more interested in histones and their modifications versus DNA methylation when it comes to epigenetics and chromatin. In part this has just been because I have studied histones so much more. For example, we have been knocking out the two histone variant H3.3 genes, H3f3a and H3f3b, now for a decade. My lab also …
Weekly reads: DNA methylation, H3 K27M in glioma, memory wipe, teeth Read More »
Early during my postdoc I was primarily interested in the role of Myc genes both in cancer and in stem cells, work that later included embryonic stem cells. These cells are often called ES cells. At first I first started studying N-Myc in neural stem cells using a conditional knockout approach. However, soon after I was …
Weekly reads: embryonic stem cells, Parkinson’s, Alzheimer’s Read More »
A days ago the news came about Mesoblast not getting FDA approval for its MSC product for GvHD. The MSC area has had a rough few years with various clinical trials including for COVID. The “stem cells for heart disease” arena has also had a tough time. Here’s more news along these lines: BioCardia pauses enrollment in PhIII trial …
Weekly reads: BioCardia, HeLa suit, illegal bio lab in CA Read More »
The Bay Area biotech Conception Bio has an intriguing name. What does “conception” mean here? Scientists can make many things from stem cells. For example, lately I’ve written a lot about stem cell-based human embryo models. Another intriguing area is called in vitro gametogenesis or IVG, where Conception Bio is a leader. IVG means making …
Weekly reads: Conception Bio & IVG, MYC, Stanford Prez resigns Read More »
Imagine regularly having someone rub your face all over with the equivalent of a small roller covered with spikes and doused with either your blood or someone else’s and you have what’s called vampire facials. There’s more news that this is a very bad idea. Vampire facials linked to more HIV cases “Vampire facials” promoted …
Weekly reads: HIV from vampire facials, CAR-T, FDA warns Regenative Labs Read More »
Where do things stand with the investigative approach of stem cells for diabetes? 33% of Type 1 Diabetes Patients Insulin-Free With Stem Cells, Medscape. Not the best headline given the few number of participants here. If your study has only two subjects and one responds, someone is going to say, “50% of people had a …
Weekly reads: Vertex stem cells for diabetes update, new CRISPR , immortality Read More »
There is still plenty of reason to worry about unproven stem cells being marketed in the U.S. and elsewhere around the world. I’ll start with a new item here in the U.S. on a firm called MD Stem Cells and end with a newly published paper about how things are going in Poland on this …
Weekly reads: MD Stem Cells, embryo models & headaches, cell therapy trial updates Read More »